Tag Archives: Elusys Therapeutics

March, 2016

  • 21 March

    FDA Approves Anthim Injection for Treatment of Inhalational Anthrax

    On Friday, March 18, the U.S. Food and Drug Administration approved Anthim (obiltoxaximab) injection to treat inhalational anthrax in combination with appropriate antibacterial drugs. Anthim is also approved to prevent inhalational anthrax when alternative therapies are not available or not appropriate. Inhalational anthrax is a rare disease that can occur …